Biomarkers and treatment methods for traumatic brain injury-associated impairments
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorAmy Kathleen Wagner
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods, compositions, and kits for treating traumatic brain injury (TBI) and TBI-associated impairments in a subject. The methods include administering to the subject an interleukin-7 (IL-7) or IL-7 agonist, a tumor necrosis factor alpha (TNFα) inhibitor, or both. The present disclosure also relates to methods of using biomarkers for identifying a subject that is likely to respond to a treatment for TBI-associated impairments, and monitoring the subject's response to such treatment.
Claims11
A method of treating a traumatic brain injury (TBI)-associated impairment, in a subject that has sustained a TBI, comprising administering to the subject a TNFα inhibitor, wherein the TNFα inhibitor is selected from the group comprising etanercept, etanercept-szzs, adalimumab, adalimumab-adbm, adalimumab-adaz, adalimumab-atto, and golimumab.
A method for treating a TBI-associated impairment in a subject that has sustained a TBI, comprising:
- (a) determining a level of Neutrophil-Lymphocyte Ratio (NLR) and a level of IL-7 in at least two samples obtained from the subject;
- (b) comparing the level of NLR to a reference level of NLR and the level of IL-7 to a reference level of IL-7,
- wherein the reference levels of NLR and IL-7 are predetermined levels,
- wherein the predetermined levels of NLR and IL-7 are from (i) a healthy individual or a population of healthy individuals free of the TBI-associated impairment or (ii) the same subject collected at an earlier time point,
- wherein the reference level of IL-7 is about 25 μg/ml, and
- wherein the reference level of NLR is about 10;
- (c) assigning trajectory group memberships to the subject by assessing the IL-7 and NLR levels of the subject in relation to group-based trajectory analyses derived from a population with TBI,
- wherein if the level of IL-7 is lower than the reference level of the IL-7 the subject is assigned a low IL-7 trajectory group membership,
- wherein if the level of IL-7 is higher than the reference level of the IL-7 the subject is assigned a high IL-7 trajectory group membership,
- wherein if the level of NLR is lower than the reference level of NLR the subject is assigned a low NLR trajectory group membership,
- wherein if the level of NLR is higher than the reference level of NLR the subject is assigned a high NLR trajectory group membership;
- and
- (c-i) treating the subject with IL-7 if the subject is assigned a low IL-7 trajectory group membership and a low NLR trajectory group membership,
- (c-ii) treating the subject with IL-7 and etanercept if the subject is assigned a low IL-7 trajectory group membership and a high NLR trajectory group membership;
- or (c-iii) treating the subject with etanercept if the subject is assigned a high IL-7 trajectory group membership and a high NLR trajectory group membership.
Dependencies are inferred from the claim text.